BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $830 | -14.5% | 12,197 | +2.6% | 0.01% | -14.3% |
| Q2 2023 | $971 | -25.0% | 11,891 | -31.9% | 0.01% | -22.2% |
| Q1 2023 | $1,295 | -80.0% | 17,459 | -77.7% | 0.01% | -80.9% |
| Q4 2022 | $6,480 | -99.8% | 78,180 | +650.1% | 0.05% | +123.8% |
| Q3 2022 | $2,960,000 | +41.8% | 10,423 | +73.1% | 0.02% | +50.0% |
| Q2 2022 | $2,087,000 | -40.5% | 6,022 | -25.6% | 0.01% | -22.2% |
| Q1 2022 | $3,507,000 | -10.7% | 8,098 | +6.7% | 0.02% | 0.0% |
| Q4 2021 | $3,928,000 | -44.1% | 7,592 | -47.6% | 0.02% | -52.6% |
| Q3 2021 | $7,024,000 | -5.7% | 14,496 | -12.4% | 0.04% | -7.3% |
| Q2 2021 | $7,448,000 | +355.3% | 16,542 | +286.1% | 0.04% | +355.6% |
| Q1 2021 | $1,636,000 | +47.1% | 4,284 | +22.3% | 0.01% | +28.6% |
| Q4 2020 | $1,112,000 | +104.8% | 3,502 | +59.7% | 0.01% | +75.0% |
| Q3 2020 | $543,000 | +64.0% | 2,193 | +74.7% | 0.00% | +33.3% |
| Q2 2020 | $331,000 | -63.3% | 1,255 | -71.6% | 0.00% | -50.0% |
| Q3 2018 | $902,000 | -19.8% | 4,420 | -41.8% | 0.01% | -14.3% |
| Q2 2018 | $1,124,000 | -10.2% | 7,600 | -8.3% | 0.01% | -12.5% |
| Q1 2018 | $1,252,000 | -24.2% | 8,288 | -35.0% | 0.01% | -27.3% |
| Q4 2017 | $1,652,000 | +342.9% | 12,753 | +313.7% | 0.01% | +450.0% |
| Q3 2017 | $373,000 | -65.8% | 3,083 | -66.8% | 0.00% | -75.0% |
| Q2 2017 | $1,092,000 | +260.4% | 9,291 | +212.2% | 0.01% | +300.0% |
| Q1 2017 | $303,000 | -2.6% | 2,976 | -1.7% | 0.00% | 0.0% |
| Q4 2016 | $311,000 | -30.0% | 3,026 | -25.3% | 0.00% | -33.3% |
| Q3 2016 | $444,000 | -24.4% | 4,053 | -22.1% | 0.00% | -25.0% |
| Q2 2016 | $587,000 | +35.9% | 5,206 | +13.8% | 0.00% | +33.3% |
| Q1 2016 | $432,000 | +38.9% | 4,574 | +32.4% | 0.00% | +50.0% |
| Q4 2015 | $311,000 | -26.3% | 3,455 | -24.4% | 0.00% | -33.3% |
| Q3 2015 | $422,000 | +197.2% | 4,568 | +216.6% | 0.00% | +200.0% |
| Q2 2015 | $142,000 | -73.6% | 1,443 | -73.0% | 0.00% | -75.0% |
| Q1 2015 | $537,000 | +416.3% | 5,350 | +377.3% | 0.00% | +300.0% |
| Q4 2014 | $104,000 | – | 1,121 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |